Halozyme Therapeutics saw a welcome improvement to its Relative Strength (RS) Rating on Monday, with an upgrade from 84 to 92.
IBD's unique RS Rating tracks market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
Over 100 years of market history reveals that the best-performing stocks typically have an 80 or better RS Rating at the beginning of a new climb.
Here Are 3 Keys For Successful Stock Investing
Halozyme Therapeutics is building a consolidation with a 65.53 buy point. See if it can clear the breakout price in volume at least 40% higher than normal.
The company saw both earnings and sales growth rise last quarter. Earnings-per-share increased from 23% to 69%. Revenue rose from 5% to 34%.
The company holds the No. 1 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis and Halozyme Therapeutics are also among the group's highest-rated stocks.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
